A Clinical Introduction to Mydayis for Treatment of ADHD

JANUARY 10, 2018
This article is sponsored by Shire US Inc.

Attention-deficit/hyperactive disorder (ADHD) is a neurodevelopmental disorder that emerges before the age of 12 years. Affected individuals may have symptoms of inattention, impulsivity, and hyperactivity that are not better explained by another medical condition. ADHD may impair academic, social or occupational functioning.1

Approved by the FDA in June 2017, Mydayis (mixed salts of a single-entity amphetamine product) is an ADHD medication indicated for use in patients 13 years and older. Patients ≤12 years experienced higher plasma exposure at the same dose and higher rates of adverse reactions, mainly insomnia and decreased appetite. Mydayis provides an additional treatment option for adolescents and adults with ADHD.2

To read the full monograph, please see the link below following the Important Safety Information.

  • CNS stimulants, including Mydayis, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
  • Contraindications
    • Known hypersensitivity to amphetamines or other ingredients of Mydayis. Angioedema and anaphylactic reactions have been reported with other amphetamines.
    • Use with monoamine oxidase inhibitors (MAOIs) or within 14 days of last MAOI dose, due to increased risk of hypertensive crisis.
  • Warnings and Precautions
    • Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulants at recommended doses, as well as sudden death in pediatric patients with structural cardiac abnormalities and other serious heart problems while taking CNS stimulants at recommended doses. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during Mydayis treatment.
    • CNS stimulants cause increased blood pressure (mean increase ~2-4 mm Hg) and heart rate (mean increase ~3-6 bpm). Monitor for tachycardia and hypertension.
    • Exacerbation of Pre-existing Psychosis: May exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Induction of a Manic Episode in Patients with Bipolar Disorder: May induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms, or a family history of suicide, bipolar disorder, and depression). New Psychotic or Manic Symptoms: At recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients with no prior history of psychotic illness or mania. Discontinue if symptoms occur.
    • CNS stimulants are associated with weight loss and slowing of growth rate in pediatric patients (monitor weight and height). Treatment may need to be interrupted in patients not growing or gaining weight as expected. Mydayis is not approved in pediatric patients ≤12 years.
    • CNS stimulants are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/ or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with ADHD stimulants; further evaluation and referral may be required.
    • Mydayis may lower the convulsive threshold in patients with prior history of seizure, prior EEG abnormalities in the absence of seizures, and in patients without a history of seizures and no prior EEG evidence of seizures. Discontinue if a seizure occurs.
    • Increased risk of serotonin syndrome when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. Discontinue Mydayis if it occurs and initiate supportive treatment.
    • To avoid substitution errors and overdosage, do not substitute for other amphetamines on a mg-per-mg basis because of different amphetamine base compositions and differing PK profiles.
  • Adverse Reactions
    Most common adverse reactions in patients with ADHD (incidence ≥5% and at a rate at least twice placebo) are:
    • Pediatrics (13 years and older): insomnia, decreased appetite, decreased weight, irritability, and nausea.
    • Adults: insomnia, decreased appetite, decreased weight, dry mouth, increased heart rate, and anxiety.
  • Pregnancy and Lactation
    Mydayis may cause fetal harm. Breastfeeding is not recommended during Mydayis treatment.

Please click for .

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088.

To access the Clinical Monograph, or the image below.

  1. Attention-deficit/hyperactivity disorder. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
  2. Mydayis [package insert]. Lexington, MA: Shire LLC; 2017.

MYDAYIS is a registered trademark and the Mydayis logo is a trademark of Shire LLC. 
SHIRE and the Shire logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
©2017 Shire US Inc., Lexington MA 02421. All rights reserved. 1-800-828-2088. S35887 10/17

Plantsvszombies.info Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Personalize the information you receive by selecting targeted content and special offers.